<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Psychiatry</journal-id><journal-title>BMC Psychiatry</journal-title><issn pub-type="epub">1471-244X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-244X-9-17</article-id><article-id pub-id-type="pmid">19405953</article-id><article-id pub-id-type="doi">10.1186/1471-244X-9-17</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Martins-de-Souza</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>martins@mpipsykl.mpg.de</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Gattaz</surname><given-names>Wagner F</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>gattaz@usp.br</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Schmitt</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>aschmit@gwdg.de</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Novello</surname><given-names>Jos&#x000e9; C</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>jcn@unicamp.br</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Marangoni</surname><given-names>S&#x000e9;rgio</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>marango@unicamp.br</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Turck</surname><given-names>Christoph W</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>turck@mpipsykl.mpg.de</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Dias-Neto</surname><given-names>Emmanuel</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I5">5</xref><email>emmanuel@usp.br</email></contrib></contrib-group><aff id="I1"><label>1</label>Laborat&#x000f3;rio de Neuroci&#x000ea;ncias, Instituto de Psiquiatria, Faculdade de Medicina da USP, Rua Dr. Ov&#x000ed;dio Pires de Campos, no 785, S&#x000e3;o Paulo, SP, CEP 05403-010, Brazil</aff><aff id="I2"><label>2</label>Max Planck Institute of Psychiatry, Kraepelinstrasse 2, D-80804, Munich, Germany</aff><aff id="I3"><label>3</label>Departamento de Bioqu&#x000ed;mica, Instituto de Biologia, UNICAMP, CEP 13083-970, Campinas, SP, Brazil</aff><aff id="I4"><label>4</label>Department of Psychiatry, Von Siebold Str. 5, University of Goettingen, 37075 Goettingen, Germany</aff><aff id="I5"><label>5</label>University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, Texas, USA</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>30</day><month>4</month><year>2009</year></pub-date><volume>9</volume><fpage>17</fpage><lpage>17</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-244X/9/17"/><history><date date-type="received"><day>13</day><month>10</month><year>2008</year></date><date date-type="accepted"><day>30</day><month>4</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Martins-de-Souza et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Martins-de-Souza et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Martins-de-Souza Daniel martins@mpipsykl.mpg.de </dc:author><dc:title> Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>BMC Psychiatry 9(1): 17-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-244X(2009)9:1&#x0003c;17&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-244X</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Schizophrenia is likely to be a consequence of DNA alterations that, together with environmental factors, will lead to protein expression differences and the ultimate establishment of the illness. The superior temporal gyrus is implicated in schizophrenia and executes functions such as the processing of speech, language skills and sound processing.</p></sec><sec sec-type="methods"><title>Methods</title><p>We performed an individual comparative proteome analysis using two-dimensional gel electrophoresis of 9 schizophrenia and 6 healthy control patients' left posterior superior temporal gyrus (Wernicke's area &#x02013; BA22p) identifying by mass spectrometry several protein expression alterations that could be related to the disease.</p></sec><sec><title>Results</title><p>Our analysis revealed 11 downregulated and 14 upregulated proteins, most of them related to energy metabolism. Whereas many of the identified proteins have been previously implicated in schizophrenia, such as fructose-bisphosphate aldolase C, creatine kinase and neuron-specific enolase, new putative disease markers were also identified such as dihydrolipoyl dehydrogenase, tropomyosin 3, breast cancer metastasis-suppressor 1, heterogeneous nuclear ribonucleoproteins C1/C2 and phosphate carrier protein, mitochondrial precursor. Besides, the differential expression of peroxiredoxin 6 (PRDX6) and glial fibrillary acidic protein (GFAP) were confirmed by western blot in schizophrenia prefrontal cortex.</p></sec><sec><title>Conclusion</title><p>Our data supports a dysregulation of energy metabolism in schizophrenia as well as suggests new markers that may contribute to a better understanding of this complex disease.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Several studies using global gene expression and proteomics analyses in different brain regions of schizophrenia (SCZ) patients have revealed dysfunctions in synaptogenesis and neural plasticity, energy metabolism, cytoskeleton assembly and oligodendrocyte metabolism [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B13">13</xref>].</p><p>One of the main clinical features in SCZ is the inappropriate use of language such as preservations, low verbal fluency, or absent-mindedness with use of incoherent language. They can be assumed under formal thought disorders and represent reliable diagnostic criteria for schizophrenia. As a complex and dynamic cognitive system that integrates multiple levels of linguistic and cognitive processing, language can be distinguished in micro- and macrolinguistic dimensions that are compromised in SCZ [reviewed in [<xref ref-type="bibr" rid="B14">14</xref>]]. The superior temporal gyrus (STG), which is part of the human temporal lobe, is the major brain area related to speech, language and communication. Injuries such as tumors, stroke or epilepsy affecting the STG may lead to disturbances of language function and hallucinations similar to those observed in SCZ symptoms [<xref ref-type="bibr" rid="B15">15</xref>]. The left STG (L-STG) gray matter was shown altered compared to the right STG as well as the brain symmetry in SCZ patients [<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B19">19</xref>]. Interestingly, the volume of the L-STG cortex was negatively correlated with deficit symptoms [<xref ref-type="bibr" rid="B18">18</xref>] and was shown to be decreased to a larger extent in patients with poor-outcome compared to those with good outcomes [<xref ref-type="bibr" rid="B20">20</xref>]. Binding sites of the glutamatergic N-methyl-D-aspartic acid (NMDA) receptor have been reported to be increased in the STG to a greater extent on the left side in patients with predominantly negative symptoms [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>]. The L-STG, specialized in language skills, is formed by the primary auditory cortex (Brodmann's Areas (BA) 41 and 42) and the Wernicke's area (WA), also described as the posterior region of BA22. WA is an important region for speech processing and language skills.</p><p>We performed comparative individual proteomic analyses of L-STG (WA or BA22p) tissues of 9 SCZ patients and 6 controls, using two-dimensional gel electrophoresis (2-DE), followed by MALDI-TOF/TOF (Matrix-Assisted Laser Desorption/Ionization/Time of Flight) mass spectrometry. The 25 regulated proteins identified here include novel as well as previously reported putative SCZ markers that may be involved in disease pathobiology.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Human Wernicke's area (WA)</title><p><italic>Post-mortem </italic>brain samples from the left WA tissue (BA22p) were collected from 9 schizophrenia patients and 6 controls. Control subjects were free from psychiatry disorders, somatic diseases or brain tumors and had never been treated with antidepressant or antipsychotic medications. Brain samples were dissected by an experienced neuropathologist (median: 20.5 hours (min.7 hours &#x02013; max.37 hours) after death) and deep-frozen immediately after collection.</p><p>All samples were obtained from the brain bank of the Central Institute of Mental Health (Mannheim, Germany). Controls were collected at the Institute of Neuropathology, Heidelberg University, and clinical records were collected from relatives and general practitioners. Patient samples were derived from in-patients of the Mental State Hospital Wiesloch, Germany. All cases and controls were German whites. All SCZ patients were long-term in-patients at the Mental State Hospital Wiesloch, Germany, and SCZ diagnosis was made <italic>ante-mortem </italic>by an experienced psychiatrist according to the DSM-IV criteria [<xref ref-type="bibr" rid="B23">23</xref>]. For each patient the antipsychotic treatment history was assessed by examining the medical charts and calculated in chlorpromazine equivalents (CPE), through the algorithm developed by Jahn and Mussgay [<xref ref-type="bibr" rid="B24">24</xref>] for typical neuroleptics and clozapine. The CPE of olanzapine was calculated using the mean doses described by Meltzer and Fatemi [<xref ref-type="bibr" rid="B25">25</xref>]. All patients and controls underwent neuropathologic characterization to rule out associated neurovascular or neurodegenerative disorders. The classification according to Braak was stage II or less for all subjects [<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>]. Patients and controls had no history of alcohol or drug abuse and severe physical illness. All assessments and <italic>post-mortem </italic>evaluations and procedures were previously approved by the ethics committee of the Faculty of Medicine of Heidelberg University, Germany. Detailed patient information is given in Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>.</p></sec><sec><title>Sample Preparation</title><p>Fifty milligrams of human WA were individually homogenized in 1.5 ml tubes with glass spheres in 200 &#x003bc;l of 7 M urea, 2 M thiourea, 4% CHAPS, 2% ASB-14 and 70 mM DTT buffer [<xref ref-type="bibr" rid="B28">28</xref>]. Samples were centrifuged for 10 min at 14,000 rpm and quantified [<xref ref-type="bibr" rid="B29">29</xref>]. Supernatants were used for 2-DE.</p></sec><sec><title>Two-Dimensional Gel Electrophoresis</title><p>Using two-dimensional gel electrophoresis we performed an individual proteome analysis of 9 schizophrenia samples compared to a pool of 6 healthy control. The experiments were carried out as described by Martins-de-Souza et al. [<xref ref-type="bibr" rid="B28">28</xref>]. Briefly, 650 &#x003bc;g of protein from SCZ or control samples were applied to IPG gel strips with a nonlinear separation range of pH 3&#x02013;10 prior the second dimension in 12.5% T acrylamide gels that were stained using a colloidal coomassie blue protocol.</p><p>All experiments were performed in triplicate. Only proteins that appeared to be differentially expressed in triplicate gels were considered as differentially regulated.</p></sec><sec><title>Determination of protein expression differences and protein identification by peptide mass fingerprinting</title><p>2-DE gel images were used for spot detection and pI/MW calibration of WA samples using the ImageMaster 2D software, (GE Healthcare, Uppsala, Sweden). A total of thirty 2-DE profiles were analyzed, consisting of 27 gels from patients (9 patients evaluated individually in triplicates) plus three gels for the controls (triplicates of pooled controls). Volumes of all spots in SCZ and CTRL gels were determined and corresponding spots were matched for all 2-DE profiles. The spot volumes were analyzed by Kruskal-Wallis one-way analysis of variance aiming to reveal the statistically significant differences in the protein expression between the two groups. Protein spots with a mean n-fold change between SCZ and CTRL WA gels of +/- 1.8 were excised for mass spectrometry (MS) identification. False discovery rate (FDR) was calculated according to Storey, 2002 [<xref ref-type="bibr" rid="B30">30</xref>]<ext-link ext-link-type="uri" xlink:href="http://www.genomine.org/qvalue/index.html"/>. Protein identification by peptide mass fingerprinting was done as described by Martins-de-Souza et al. [<xref ref-type="bibr" rid="B31">31</xref>].</p></sec><sec><title>Western Blot</title><p>For western blot analysis, proteins were extracted as described above. One-hundred &#x003bc;g of total protein from dorsolateral prefrontal cortex (DLPFC) were run on a 12% SDS minigel (Bio-Rad, Hercules, CA, USA) and the proteins were transferred to Immobilon PVDF membranes (Millipore, Bedford, MA) at 100 V for 1 h with cooling. Membranes were treated with 5% Carnation instant nonfat dry milk in TBS-T for 4 hours, rinsed in TBS-T 3 times for 20 minutes and incubated with anti-PRDX6 (Abcam, Cambridge, UK) or anti-GFAP antibodies (Abcam, Cambridge, UK) at a 1:1000 dilution in TBS-T overnight at 4&#x000b0;C. In the next day, membranes were washed with water and TBS-T for 15 min. Incubations with anti-c-MYC-peroxidase antibody (GE Healthcare, Uppsala, Sweden) were carried out for 40 min at room temperature, followed by membrane washing with water and TBS-T and incubation with ECL mixture (GE Healthcare, Uppsala, Sweden) for 1 min and ECL film exposure (GE Healthcare, Uppsala, Sweden). Films were scanned, and the band signals (optical densities) were assessed using QuantityOne software (Bio-Rad, Hercules, CA, USA).</p></sec><sec><title>Protein classification</title><p>Differentially expressed proteins were classified according to their main biological processes as well as their molecular functions using Human Protein Reference Database (HPRD &#x02013; <ext-link ext-link-type="uri" xlink:href="http://www.hprd.org"/>). Moreover, the WA differentially expressed proteins were classified according their biochemical pathways using KEGG analysis <ext-link ext-link-type="uri" xlink:href="http://www.genome.jp/kegg"/> through software "Blast2Go" <ext-link ext-link-type="uri" xlink:href="http://www.blast2go.org"/>.</p></sec></sec><sec><title>Results</title><p>On average, 669 protein spots were detected in SCZ 2-DE profiles whereas 605 protein spots were detected in CTRL 2-DE profiles (Figure <xref ref-type="fig" rid="F1">1A</xref>). There were 553 matched spots between the groups, representing 86.8% of the average number of spots. When individual SCZ gels and pool control gels were compared, 30 spots (~4,7%) were consistently identified with significant changes in relative abundance (&#x0003e; 1.4 fold difference, P &#x0003c; 0.05, Kruskal-Wallis) (Additional file <xref ref-type="supplementary-material" rid="S2">2</xref>) [<xref ref-type="bibr" rid="B31">31</xref>-<xref ref-type="bibr" rid="B38">38</xref>]. These 30 spots revealed 25 distinct proteins with apparent altered regulation (11 downregulated and 14 upregulated in SCZ samples; Figure <xref ref-type="fig" rid="F1">1</xref>). Twenty-three proteins were identified as single spots and two proteins were identified in multiple spots (spots C05, C06, C07, C10 and C08, C09; Figure <xref ref-type="fig" rid="F1">1</xref>). All 25 proteins were successfully identified by MALDI-TOF/TOF and grouped according to their biological processes and molecular function using the Human Protein Reference Database (HPRD &#x02013; <ext-link ext-link-type="uri" xlink:href="http://www.hprd.org"/>) (Figure <xref ref-type="fig" rid="F2">2A</xref> and Figure <xref ref-type="fig" rid="F2">2B</xref> and Additional file <xref ref-type="supplementary-material" rid="S2">2</xref>). Equivalent areas of four distinct 2-DE gels are presented in the Figure <xref ref-type="fig" rid="F1">1D</xref> and <xref ref-type="fig" rid="F1">1E</xref> as an example of the reproducibility of the protein profiles.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Representative 2-DE profile of Wernicke's area from schizophrenia samples is presented in A</bold>. The "S" means spot upregulation in SCZ and "C" spot upregulation in CTRL. Examples of proteins upregulated in CTRL brains are presented in the enlarged sections of the 2-DE profile (B and C). The reproducibility of the 2-DE profiles is demonstrated by the sections of four gels shown in D and E.</p></caption><graphic xlink:href="1471-244X-9-17-1"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>(A) Biological processes and (B) molecular functions of differentially expressed WA proteins in SCZ</bold>. (C) KEGG analysis showed that some of the differentially expressed enzymes identified here (ALDOC, TPI1, GAPDH, PGAM, ENO2 and DLD) belongs to the same glucose-related pathway.</p></caption><graphic xlink:href="1471-244X-9-17-2"/></fig></sec><sec><title>Discussion</title><p>Our findings support previous reports on altered protein expression in SCZ as well as suggest new targets that may be relevant for the pathobiology of this disease. The main pathways and proteins observed are discussed bellow.</p><sec><title>Energy metabolism dysregulation</title><p>Most proteins we identified as differentially expressed (52%) are enzymes involved the regulation of energy metabolism. Their altered levels can lead to an overall disturbance, and ultimately contribute to the establishment of pathological states [<xref ref-type="bibr" rid="B39">39</xref>,<xref ref-type="bibr" rid="B40">40</xref>]. In this regard, a recent report has suggested that brain evolution from monkeys to humans may have led to the appearance of SCZ due to changes affecting energy pathway genes [<xref ref-type="bibr" rid="B41">41</xref>]. The alteration of this pathway, specifically the glycolysis and gluconeogenesis pathways in the WA is strongly supported by our data (Figure <xref ref-type="fig" rid="F2">2C</xref>).</p><p>Enzymes with functions in glycolysis such as ALDOC (Aldolase C), TPI1 (Triosephosphate isomerase 1), GAPDH (Glyceraldehyde-3-phosphate dehydrogenase), PGAM1 (Phosphoglycerate mutase 1) and ENO2 (Enolase 2) were found to be differentially expressed in WA, and are very likely to affect the glucose metabolism in SCZ patients. Likewise a dysfunction in ATP metabolism can result from differentially expressed ATP synthase subunits, ATP6V1A (ATPase, H+ transporting, lysosomal 70 kDa, V1 subunit A) and ATP5A1 (ATP synthase subunit alpha, mitochondrial). The above-mentioned proteins, and in some cases their genes, have been previously found to be differentially expressed in SCZ (Additional file <xref ref-type="supplementary-material" rid="S2">2</xref>).</p><p>We also found the differential regulation of dihydropteridine reductase (QDPR upregulated: 2.25&#x000d7;), which has been previously found to be differentially regulated [<xref ref-type="bibr" rid="B7">7</xref>] in 10 SCZ patients compared to 10 paired controls. This enzyme is a key in the control of dopamine and serotonin synthesis [<xref ref-type="bibr" rid="B42">42</xref>].</p><p>In our analyses we also found two new energy-metabolism-related proteins to be regulated in SCZ, which may have important roles SCZ negative symptoms: dihydrolipoyl dehydrogenase (DLD: upregulated: 2.17&#x000d7;) and peroxiredoxin 6 (PRDX6 upregulated: 2.33&#x000d7;). DLD is a component enzyme of complexes such as pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, and the branched-chain alpha-keto acide dehydrogenase which participate in cell redox processes. PRDX6 is a bifunctional enzyme with two active sites with distinct roles. This enzyme is involved in redox regulation protecting the cell against oxidative injury by reducing levels of H<sub>2</sub>O<sub>2</sub>, short chain organic fatty-acids and phospholipid hydroperoxides [<xref ref-type="bibr" rid="B43">43</xref>]. Oxidative stress that can lead to DNA damage, protein inactivation, altered gene expression and apoptotic events, probably starts in SCZ during neurodevelopment. The close connection of these mechanisms to neuronal plasticity suggests that an oxidative component may be relevant to disease pathogenesis [<xref ref-type="bibr" rid="B39">39</xref>,<xref ref-type="bibr" rid="B40">40</xref>,<xref ref-type="bibr" rid="B44">44</xref>]. Thus, it is plausible that the differential regulation of an oxidative protector like PRDX6 may contribute to pathogenesis. The phospholipase A2 (PLA2) activity of PRDX6 on the other hand is critical for the regulation of phospholipid turnover [<xref ref-type="bibr" rid="B43">43</xref>]. An accelerated PLA2-mediated phospholipid turnover was previously observed in SCZ frontal lobe [<xref ref-type="bibr" rid="B45">45</xref>] whereas an increased activity of Ca<sup>2+</sup>-dependent PLA2 may lead to a reduced brain dopaminergic activity [<xref ref-type="bibr" rid="B45">45</xref>,<xref ref-type="bibr" rid="B46">46</xref>]. The differential regulation of PRDX6 may accelerate the phospholipid turnover, leading to the described differential dopaminergic state. As both PRDX6 activities seem to be related to SCZ pathogenesis, we analyzed PRDX6 protein expression by western blot (WB) in the DLPFC of SCZ patients (Figure <xref ref-type="fig" rid="F3">3A</xref>). Again, a significant differential expression of PRDX6 was found (Figure <xref ref-type="fig" rid="F3">3B</xref>). Moreover, it is interesting to note that PRDX6 gene is localized in a chromosome loci (1q25.1) previously related with SCZ [<xref ref-type="bibr" rid="B47">47</xref>].</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>(A) Western-blot profiles of PRDX6 and GFAP in the dorsolateral prefrontal cortex from SCZ and controls</bold>. The intensity of the western-blot bands for both proteins and the statistical analysis by Mann-Whitney are presented in B and C.</p></caption><graphic xlink:href="1471-244X-9-17-3"/></fig><p>Although a correlation between the differential expression of glucose metabolism and oxidative phosphorylation enzymes has been recently described in SCZ [<xref ref-type="bibr" rid="B48">48</xref>], there is no consensus whether the protein expression alterations are causes or consequences of a pathological process. Also, the mitochondrial protein alterations found in SCZ could be consequences of the medications used by patients [<xref ref-type="bibr" rid="B32">32</xref>]. However, alterations in the glucose metabolism have been extensively reported as a central component of SCZ and are unlikely due to antipsychotic effects [<xref ref-type="bibr" rid="B41">41</xref>,<xref ref-type="bibr" rid="B49">49</xref>].</p></sec><sec><title>Tubulin</title><p>Tubulins are involved in multiple activities, including mitosis, cytokinesis, and vesicular transport. Alterations of tubulin subunits have been described in SCZ [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B50">50</xref>] and were also found in WA in our study (Additional file <xref ref-type="supplementary-material" rid="S2">2</xref>). Importantly, possible roles of tubulin in SCZ have been suggested by Denarier et al. [<xref ref-type="bibr" rid="B51">51</xref>] who generated a mouse SCZ model by knocking out the stable tubulin-only polypeptide (STOP) gene, which is responsible for microtubule stabilization in neurons. STOP null mice have a normal brain anatomy but show synaptic function defects due to dysfunctional glutamatergic transmission [<xref ref-type="bibr" rid="B52">52</xref>]. Moreover, this model exhibits a hyperdopaminergic state in the limbic system [<xref ref-type="bibr" rid="B53">53</xref>].</p></sec><sec><title>Other potential markers for schizophrenia</title><sec><title>Glial Fibrillary Acidic Protein (GFAP)</title><p>Astrocyte abnormality is a recurrent finding in SCZ. Among other functions, astrocytes are responsible for the maintenance of glutamatergic transmission <italic>via </italic>the glutamate-glutamine cycle [<xref ref-type="bibr" rid="B54">54</xref>]. Glial fibrillary acidic protein (GFAP &#x02013; upregulated: 2.31&#x000d7;) is the major intermediate filament (IF) protein of mature astrocytes. Modifications in the expression of this structural protein have been reported in SCZ (Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>) and can lead to compromised synaptic functioning and behavior alterations [reviewed in [<xref ref-type="bibr" rid="B54">54</xref>]]. The over expression of GFAP, suggested by our 2-DE analysis was also evaluated and confirmed by western-blot in individual samples of SCZ-DLPFC (Figures <xref ref-type="fig" rid="F3">3A</xref> and <xref ref-type="fig" rid="F3">3C</xref>), reinforcing its potential role in SCZ.</p></sec><sec><title>Phosphatidylethanolamine-binding protein (PEBP1)</title><p>Phosphatidylethanolamine-binding protein 1 (PEBP1 &#x02013; upregulated: 1.87&#x000d7;) has functions in membrane biogenesis and signaling mechanisms during cell growth and maturation. PEBP1 is a calpain substrate that has been implicated in processes that produce persistent changes in synaptic chemistry and structure [<xref ref-type="bibr" rid="B55">55</xref>]. A PEBP1 knockout mouse has been reported in 2007 [<xref ref-type="bibr" rid="B56">56</xref>], and revealed some interesting associations of this protein in the control of emotions and complex behavior responses. PEBP1 -/- mice suffer from a decline of the smell sense and reproduction without any obvious fertility defects. PEBP1 appears to be upregulated in the aggression and fear controlling amygdala. In a mouse model of Alzheimer's disease the loss of PEBP1 function was observed and behavioral tests revealed a learning deficit [<xref ref-type="bibr" rid="B57">57</xref>].</p></sec><sec><title>Breast cancer metastasis-suppressor 1 (BRMS1)</title><p>The BRMS1 gene product seems to act as a transcriptional regulator of diverse genes [<xref ref-type="bibr" rid="B58">58</xref>], and is capable to reduce the metastatic potential of human breast cancer and melanoma cell lines. This is the first description of the putative alteration of BRMS1 in SCZ or any other neuropsychiatric condition.</p></sec></sec></sec><sec><title>Conclusion</title><p>It is important to mention that confounding factors such as other co-existing diseases, age, gender, or diet of the patients or <italic>post-mortem </italic>intervals and agonal states, can significantly impact brain proteome studies. For the particular set of samples analyzed in this study, the electrophoretic profile of proteins from individual samples from cases and controls suggests that the <italic>post-mortem </italic>intervals did not generate false proteome alterations in these particular analyses (data not shown). Moreover, we should note that all the SCZ samples used in the present work were obtained from patients that have been treated with antipsychotics. Distinct medications and distinct doses or treatment regimens can certainly impact the proteome studies presented here. We have calculated the false discovery rate (FDR) of the presented dataset using the Q-value software <ext-link ext-link-type="uri" xlink:href="http://www.genomine.org/qvalue/index.html"/> developed by Storey 2002 [<xref ref-type="bibr" rid="B30">30</xref>]. FDR is a false positive calculation method that, instead of controlling the chance of any false positives (as Bonferroni), controls the expected proportion of false positives. The q-value given by FDR is the analogue of the p-value. Briefly, the q-value is a p-value of all the p-values simultaneously. The calculated FDR was 0.0153, suggesting that our data could have an error of 1.53%. The validation of the differentially expressed proteins, as we did for GFAP and PRDX6, would be an alternative to validate the markers and to skip possible errors.</p><p>As was found for other brain regions, our data suggest an overall energy metabolism dysregulation in WA of SCZ patients. Beasley et al. [<xref ref-type="bibr" rid="B32">32</xref>] suggested that many of the observed energy metabolism alterations could be consequences of medication. On the other hand Stone et al. [<xref ref-type="bibr" rid="B49">49</xref>] state that a dysfunctional energy metabolism is a central component of SCZ and not due to an antipsychotic effect. However, studies using samples from psychotropic drug na&#x000ef;ve patients will hopefully help to resolve this issue.</p><p>Our findings are in line with a recent hypothesis of Khaitovich et al. [<xref ref-type="bibr" rid="B41">41</xref>] that states that SCZ may be a consequence of human brain development. Clustered genes that were positively selected during the evolution of the human brain were grouped into 22 functional categories, six of these (27,2%) included genes with functions related to energy metabolism, some of which previously shown to be related with SCZ. The concentration of metabolites affected by the corresponding proteins, including lactate, choline, and acetate were found to be different between SCZ and control brains. It is further suggested that human cognitive abilities are very sensitive towards alterations in metabolite levels and even slight brain energy metabolism dysregulations can lead to conditions that are hallmarks of SCZ.</p><p>The consistent individual identification of altered expression levels of the same proteins derived from patient specimens subjected to distinct therapeutic regimens support a potentially important role for these biomarkers in SCZ pathobiology. This includes PRDX6 and GFAP that were also found in DLPFC samples. Our data add to the importance of energy metabolism pathways for SCZ and have the potential to be translated to the clinic.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>This work is part of the post-doc project of DMS, who executed all the experiments and wrote the first manuscript draft. WFG and AS provided the brain samples, clinical data, and contributed to the manuscript writing and scientific discussions. SM and JCN provided the support for 2-DE analysis and mass spectrometry. CWT provided guidance for the mass spectrometry and western blot analysis and contributed to the manuscript writing. SM and EDN supervised this work and the manuscript writing. The study was conceived by DMS and EDN. All authors contributed to and have approved the final version of this manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-244X/9/17/prepub"/></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p><bold>Table 1</bold>. Patient and control clinical data. Using Mann-Whitney test, we found no significant differences between patients and controls for age (p = 0.5959), PMI (p = 0.2888) and pH (p = 0.7237).</p></caption><media xlink:href="1471-244X-9-17-S1.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><caption><title>Additional file 2</title><p><bold>Table 2</bold>. Proteins regulated in schizophrenia samples, classified according to their biological and molecular function. The accession numbers are from the Swiss-Prot database.</p></caption><media xlink:href="1471-244X-9-17-S2.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>The authors thank ABADHS (Associa&#x000e7;&#x000e3;o Beneficente Alzira Denise Hertzog da Silva), FAPESP (Funda&#x000e7;&#x000e3;o de Amparo a Pesquisa do Estado de S&#x000e3;o Paulo) and CNPq (Conselho Nacional de Desenvolvimento Cient&#x000ed;fico e Tecnol&#x000f3;gico) for supporting this project. Moreover, we thank Dr. Alessandro dos Santos Farias for the support in statistical tests and we appreciate the tissue donors' families who become possible our studies.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mirnics</surname><given-names>K</given-names></name><name><surname>Middleton</surname><given-names>FA</given-names></name><name><surname>Marquez</surname><given-names>A</given-names></name><name><surname>Lewis</surname><given-names>DA</given-names></name><name><surname>Levitt</surname><given-names>P</given-names></name></person-group><article-title>Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex</article-title><source>Neuron</source><year>2000</year><volume>28</volume><fpage>53</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">11086983</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hakak</surname><given-names>Y</given-names></name><name><surname>Walker</surname><given-names>JR</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Wong</surname><given-names>WH</given-names></name><name><surname>Davis</surname><given-names>KL</given-names></name><name><surname>Buxbaum</surname><given-names>JD</given-names></name><name><surname>Haroutunian</surname><given-names>V</given-names></name><name><surname>Fienberg</surname><given-names>AA</given-names></name></person-group><article-title>Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia</article-title><source>Proc Natl Acad Sci USA</source><year>2001</year><volume>98</volume><fpage>4746</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">11296301</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vawter</surname><given-names>MP</given-names></name><name><surname>Barrett</surname><given-names>T</given-names></name><name><surname>Cheadle</surname><given-names>C</given-names></name><name><surname>Sokolov</surname><given-names>BP</given-names></name><name><surname>Wood</surname><given-names>WH</given-names><suffix>3rd</suffix></name><name><surname>Donovan</surname><given-names>DM</given-names></name><name><surname>Webster</surname><given-names>M</given-names></name><name><surname>Freed</surname><given-names>WJ</given-names></name><name><surname>Becker</surname><given-names>KG</given-names></name></person-group><article-title>Application of cDNA microarrays to examine gene expression differences in schizophrenia</article-title><source>Brain Res Bull</source><year>2001</year><volume>55</volume><fpage>641</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">11576761</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Middleton</surname><given-names>FA</given-names></name><name><surname>Mirnics</surname><given-names>K</given-names></name><name><surname>Pierri</surname><given-names>JN</given-names></name><name><surname>Lewis</surname><given-names>DA</given-names></name><name><surname>Levitt</surname><given-names>P</given-names></name></person-group><article-title>Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia</article-title><source>J Neurosci</source><year>2002</year><volume>22</volume><fpage>2718</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">11923437</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tkachev</surname><given-names>D</given-names></name><name><surname>Mimmack</surname><given-names>ML</given-names></name><name><surname>Ryan</surname><given-names>MM</given-names></name><name><surname>Wayland</surname><given-names>M</given-names></name><name><surname>Freeman</surname><given-names>T</given-names></name><name><surname>Jones</surname><given-names>PB</given-names></name><name><surname>Starkey</surname><given-names>M</given-names></name><name><surname>Webster</surname><given-names>MJ</given-names></name><name><surname>Yolken</surname><given-names>RH</given-names></name><name><surname>Bahn</surname><given-names>S</given-names></name></person-group><article-title>Oligodendrocyte dysfunction in schizophrenia and bipolar disorder</article-title><source>Lancet</source><year>2003</year><volume>362</volume><fpage>798</fpage><lpage>805</lpage><pub-id pub-id-type="pmid">13678875</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aston</surname><given-names>C</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Sokolov</surname><given-names>BP</given-names></name></person-group><article-title>Microarray analysis of postmortem temporal cortex from patients with schizophrenia</article-title><source>J Neurosci Res</source><year>2004</year><volume>77</volume><fpage>858</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">15334603</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prabakaran</surname><given-names>S</given-names></name><name><surname>Swatton</surname><given-names>JE</given-names></name><name><surname>Ryan</surname><given-names>MM</given-names></name><name><surname>Huffaker</surname><given-names>SJ</given-names></name><name><surname>Huang</surname><given-names>JT</given-names></name><name><surname>Griffin</surname><given-names>JL</given-names></name><name><surname>Wayland</surname><given-names>M</given-names></name><name><surname>Freeman</surname><given-names>T</given-names></name><name><surname>Dudbridge</surname><given-names>F</given-names></name><name><surname>Lilley</surname><given-names>KS</given-names></name><name><surname>Karp</surname><given-names>NA</given-names></name><name><surname>Hester</surname><given-names>S</given-names></name><name><surname>Tkachev</surname><given-names>D</given-names></name><name><surname>Mimmack</surname><given-names>ML</given-names></name><name><surname>Yolken</surname><given-names>RH</given-names></name><name><surname>Webster</surname><given-names>MJ</given-names></name><name><surname>Torrey</surname><given-names>EF</given-names></name><name><surname>Bahn</surname><given-names>S</given-names></name></person-group><article-title>Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress</article-title><source>Mol Psychiatry</source><year>2004</year><volume>9</volume><fpage>684</fpage><lpage>97</lpage><comment>643.</comment><pub-id pub-id-type="pmid">15098003</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katsel</surname><given-names>P</given-names></name><name><surname>Davis</surname><given-names>KL</given-names></name><name><surname>Gorman</surname><given-names>JM</given-names></name><name><surname>Haroutunian</surname><given-names>V</given-names></name></person-group><article-title>Variations in differential gene expression patterns across multiple brain regions in schizophrenia</article-title><source>Schizophr Res</source><year>2005</year><volume>77</volume><fpage>241</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">15923110</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>D</given-names></name><name><surname>Dedova</surname><given-names>I</given-names></name><name><surname>Cordwell</surname><given-names>S</given-names></name><name><surname>Matsumoto</surname><given-names>I</given-names></name></person-group><article-title>A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia</article-title><source>Mol Psychiatry</source><year>2006</year><volume>11</volume><fpage>459</fpage><lpage>70</lpage><comment>423.</comment><pub-id pub-id-type="pmid">16491132</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Novikova</surname><given-names>SI</given-names></name><name><surname>He</surname><given-names>F</given-names></name><name><surname>Cutrufello</surname><given-names>NJ</given-names></name><name><surname>Lidow</surname><given-names>MS</given-names></name></person-group><article-title>Identification of protein biomarkers for schizophrenia and bipolar disorder in the postmortem prefrontal cortex using SELDI-TOF-MS ProteinChip profiling combined with MALDI-TOF-PSD-MS analysis</article-title><source>Neurobiol Dis</source><year>2006</year><volume>23</volume><fpage>61</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">16549361</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arion</surname><given-names>D</given-names></name><name><surname>Unger</surname><given-names>T</given-names></name><name><surname>Lewis</surname><given-names>DA</given-names></name><name><surname>Levitt</surname><given-names>P</given-names></name><name><surname>Mirnics</surname><given-names>K</given-names></name></person-group><article-title>Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia</article-title><source>Biol Psychiatry</source><year>2007</year><volume>62</volume><fpage>711</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">17568569</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sivagnanasundaram</surname><given-names>S</given-names></name><name><surname>Crossett</surname><given-names>B</given-names></name><name><surname>Dedova</surname><given-names>I</given-names></name><name><surname>Cordwell</surname><given-names>S</given-names></name><name><surname>Matsumoto</surname><given-names>I</given-names></name></person-group><article-title>Abnormal pathways in the genu of the corpus callosum in schizophrenia pathogenesis: a proteome study</article-title><source>Proteomics clin appl</source><year>2007</year><volume>1</volume><fpage>1291</fpage><lpage>1305</lpage></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pennington</surname><given-names>K</given-names></name><name><surname>Beasley</surname><given-names>CL</given-names></name><name><surname>Dicker</surname><given-names>P</given-names></name><name><surname>Fagan</surname><given-names>A</given-names></name><name><surname>English</surname><given-names>J</given-names></name><name><surname>Pariante</surname><given-names>CM</given-names></name><name><surname>Wait</surname><given-names>R</given-names></name><name><surname>Dunn</surname><given-names>MJ</given-names></name><name><surname>Cotter</surname><given-names>DR</given-names></name></person-group><article-title>Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder</article-title><source>Mol Psychiatry</source><year>2008</year><volume>13</volume><fpage>1102</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">17938637</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marini</surname><given-names>A</given-names></name><name><surname>Spoletini</surname><given-names>I</given-names></name><name><surname>Rubino</surname><given-names>IA</given-names></name><name><surname>Ciuffa</surname><given-names>M</given-names></name><name><surname>Bria</surname><given-names>P</given-names></name><name><surname>Martinotti</surname><given-names>G</given-names></name><name><surname>Banfi</surname><given-names>G</given-names></name><name><surname>Boccascino</surname><given-names>R</given-names></name><name><surname>Strom</surname><given-names>P</given-names></name><name><surname>Siracusano</surname><given-names>A</given-names></name><name><surname>Caltagirone</surname><given-names>C</given-names></name><name><surname>Spalletta</surname><given-names>G</given-names></name></person-group><article-title>The language of schizophrenia: An analysis of micro and macrolinguistic abilities and their neuropsychological correlates</article-title><source>Schizophr Res</source><year>2008</year><volume>105</volume><fpage>144</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">18768300</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rajarethinam</surname><given-names>RP</given-names></name><name><surname>DeQuardo</surname><given-names>JR</given-names></name><name><surname>Nalepa</surname><given-names>R</given-names></name><name><surname>Tandon</surname><given-names>R</given-names></name></person-group><article-title>Superior temporal gyrus in schizophrenia: a volumetric magnetic resonance imaging study</article-title><source>Schizophr Res</source><year>2000</year><volume>41</volume><fpage>303</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">10708339</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Antonova</surname><given-names>E</given-names></name><name><surname>Kumari</surname><given-names>V</given-names></name><name><surname>Morris</surname><given-names>R</given-names></name><name><surname>Halari</surname><given-names>R</given-names></name><name><surname>Anilkumar</surname><given-names>A</given-names></name><name><surname>Mehrotra</surname><given-names>R</given-names></name><name><surname>Sharma</surname><given-names>T</given-names></name></person-group><article-title>The relationship of structural alterations to cognitive deficits in schizophrenia: a voxel-based morphometry study</article-title><source>Biol Psychiatry</source><year>2005</year><volume>58</volume><fpage>457</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">16039619</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mart&#x000ed;-Bonmat&#x000ed;</surname><given-names>L</given-names></name><name><surname>Lull</surname><given-names>JJ</given-names></name><name><surname>Garc&#x000ed;a-Mart&#x000ed;</surname><given-names>G</given-names></name><name><surname>Aguilar</surname><given-names>EJ</given-names></name><name><surname>Moratal-P&#x000e9;rez</surname><given-names>D</given-names></name><name><surname>Poyatos</surname><given-names>C</given-names></name><name><surname>Robles</surname><given-names>M</given-names></name><name><surname>Sanju&#x000e1;n</surname><given-names>J</given-names></name></person-group><article-title>Chronic auditory hallucinations in schizophrenic patients: MR analysis of the coincidence between functional and morphologic abnormalities</article-title><source>Radiology</source><year>2007</year><volume>244</volume><fpage>549</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">17641373</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hazlett</surname><given-names>EA</given-names></name><name><surname>Buchsbaum</surname><given-names>MS</given-names></name><name><surname>Haznedar</surname><given-names>MM</given-names></name><name><surname>Newmark</surname><given-names>R</given-names></name><name><surname>Goldstein</surname><given-names>KE</given-names></name><name><surname>Zelmanova</surname><given-names>Y</given-names></name><name><surname>Glanton</surname><given-names>CF</given-names></name><name><surname>Torosjan</surname><given-names>Y</given-names></name><name><surname>New</surname><given-names>AS</given-names></name><name><surname>Lo</surname><given-names>JN</given-names></name><name><surname>Mitropoulou</surname><given-names>V</given-names></name><name><surname>Siever</surname><given-names>LJ</given-names></name></person-group><article-title>Cortical gray and white matter volume in unmedicated schizotypal and schizophrenia patients</article-title><source>Schizophr Res</source><year>2008</year><volume>101</volume><fpage>111</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">18272348</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garc&#x000ed;a-Mart&#x000ed;</surname><given-names>G</given-names></name><name><surname>Aguilar</surname><given-names>EJ</given-names></name><name><surname>Lull</surname><given-names>JJ</given-names></name><name><surname>Mart&#x000ed;-Bonmat&#x000ed;</surname><given-names>L</given-names></name><name><surname>Escart&#x000ed;</surname><given-names>MJ</given-names></name><name><surname>Manj&#x000f3;n</surname><given-names>JV</given-names></name><name><surname>Moratal</surname><given-names>D</given-names></name><name><surname>Robles</surname><given-names>M</given-names></name><name><surname>Sanju&#x000e1;n</surname><given-names>J</given-names></name></person-group><article-title>Schizophrenia with auditory hallucinations: a voxel-based morphometry study</article-title><source>Prog Neuropsychopharmacol Biol Psychiatry</source><year>2008</year><volume>32</volume><fpage>72</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">17716795</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitelman</surname><given-names>SA</given-names></name><name><surname>Brickman</surname><given-names>AM</given-names></name><name><surname>Shihabuddin</surname><given-names>L</given-names></name><name><surname>Newmark</surname><given-names>RE</given-names></name><name><surname>Hazlett</surname><given-names>EA</given-names></name><name><surname>Haznedar</surname><given-names>MM</given-names></name><name><surname>Buchsbaum</surname><given-names>MS</given-names></name></person-group><article-title>A comprehensive assessment of gray and white matter volumes and their relationship to outcome and severity in schizophrenia</article-title><source>Neuroimage</source><year>2007</year><volume>37</volume><fpage>449</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">17587598</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nudmamud</surname><given-names>S</given-names></name><name><surname>Reynolds</surname><given-names>GP</given-names></name></person-group><article-title>Increased density of glutamate/N-methyl-D-aspartate receptors in superior temporal cortex in schizophrenia</article-title><source>Neurosci Lett</source><year>2001</year><volume>304</volume><fpage>9</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">11335042</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grimwood</surname><given-names>S</given-names></name><name><surname>Slater</surname><given-names>P</given-names></name><name><surname>Deakin</surname><given-names>JF</given-names></name><name><surname>Hutson</surname><given-names>PH</given-names></name></person-group><article-title>NR2B-containing NMDA receptors are up-regulated in temporal cortex in schizophrenia</article-title><source>Neuroreport</source><year>1999</year><volume>10</volume><fpage>461</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">10208572</pub-id></citation></ref><ref id="B23"><citation citation-type="book"><person-group person-group-type="author"><name><surname>American</surname><given-names>PA</given-names></name></person-group><source>Diagnostic and Statistical Manual of Mental Disorders</source><year>1994</year><edition>4</edition><publisher-name>American Psychiatric Association: Washington DC</publisher-name></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jahn</surname><given-names>T</given-names></name><name><surname>Mussgay</surname><given-names>L</given-names></name></person-group><article-title>Die statistische Kontrolle m&#x000f6;glicher Medikamenteneinfl&#x000fc;sse in experimentalpsychologischen Schizophreniestudien: Ein Vorschlag zur Berechnung von Chlorpromazin&#x000e4;quivalenten</article-title><source>Z Klin Psychol</source><year>1989</year><volume>18</volume><fpage>257</fpage><lpage>267</lpage></citation></ref><ref id="B25"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Meltzer</surname><given-names>HY</given-names></name><name><surname>Fatemi</surname><given-names>SH</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Schatzberg AF, Nemeroff CB</surname></name></person-group><article-title>Treatment of schizophrenia</article-title><source>The American Psychiatric Text Book of Psychopharmacology</source><year>1998</year><edition>2</edition><publisher-name>Washington, DC: American Psychiatric Press</publisher-name><fpage>127</fpage><lpage>135</lpage></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Braak</surname><given-names>E</given-names></name></person-group><article-title>Neuropathological stageing of Alzheimer-related changes</article-title><source>Acta Neuropathol</source><year>1991</year><volume>82</volume><fpage>239</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">1759558</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Alafuzoff</surname><given-names>I</given-names></name><name><surname>Arzberger</surname><given-names>T</given-names></name><name><surname>Kretzschmar</surname><given-names>H</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name></person-group><article-title>Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry</article-title><source>Acta Neuropathol</source><year>2006</year><volume>112</volume><fpage>389</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">16906426</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martins-de-Souza</surname><given-names>D</given-names></name><name><surname>Menezes de Oliveira</surname><given-names>B</given-names></name><name><surname>dos Santos Farias</surname><given-names>A</given-names></name><name><surname>Horiuchi</surname><given-names>RS</given-names></name><name><surname>Crepaldi Domingues</surname><given-names>C</given-names></name><name><surname>de Paula</surname><given-names>E</given-names></name><name><surname>Marangoni</surname><given-names>S</given-names></name><name><surname>Gattaz</surname><given-names>WF</given-names></name><name><surname>Dias-Neto</surname><given-names>E</given-names></name><name><surname>Camillo Novello</surname><given-names>J</given-names></name></person-group><article-title>The use of ASB-14 in combination with CHAPS is the best for solubilization of human brain proteins for two-dimensional gel electrophoresis</article-title><source>Brief Funct Genomic Proteomic</source><year>2007</year><volume>6</volume><fpage>70</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">17556486</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bradford</surname><given-names>MM</given-names></name></person-group><article-title>A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding</article-title><source>Anal Biochem</source><year>1976</year><volume>72</volume><fpage>248</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">942051</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Storey</surname><given-names>JD</given-names></name></person-group><article-title>A direct approach to false discovery rates</article-title><source>J R Stat Soc Series B Stat Methodol</source><year>2002</year><volume>64</volume><fpage>479</fpage><lpage>498</lpage></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martins-de-Souza</surname><given-names>D</given-names></name><name><surname>Gattaz</surname><given-names>WF</given-names></name><name><surname>Schmitt</surname><given-names>A</given-names></name><name><surname>Maccarrone</surname><given-names>G</given-names></name><name><surname>Hunyadi-Guly&#x000e1;s</surname><given-names>E</given-names></name><name><surname>Eberlin</surname><given-names>MN</given-names></name><name><surname>Souza</surname><given-names>GH</given-names></name><name><surname>Marangoni</surname><given-names>S</given-names></name><name><surname>Novello</surname><given-names>JC</given-names></name><name><surname>Turck</surname><given-names>CW</given-names></name><name><surname>Dias-Neto</surname><given-names>E</given-names></name></person-group><article-title>Proteomic analysis of dorsolateral pre-frontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia</article-title><source>Journal of Psychiatric Research</source><comment></comment><pub-id pub-id-type="pmid">19110265</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beasley</surname><given-names>CL</given-names></name><name><surname>Pennington</surname><given-names>K</given-names></name><name><surname>Behan</surname><given-names>A</given-names></name><name><surname>Wait</surname><given-names>R</given-names></name><name><surname>Dunn</surname><given-names>MJ</given-names></name><name><surname>Cotter</surname><given-names>D</given-names></name></person-group><article-title>Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: Evidence for disease-associated changes</article-title><source>Proteomics</source><year>2006</year><volume>6</volume><fpage>3414</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">16637010</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martins-de-Souza</surname><given-names>D</given-names></name><name><surname>Gattaz</surname><given-names>WF</given-names></name><name><surname>Schmitt</surname><given-names>A</given-names></name><name><surname>Rewerts</surname><given-names>C</given-names></name><name><surname>Marangoni</surname><given-names>S</given-names></name><name><surname>Novello</surname><given-names>JC</given-names></name><name><surname>Maccarrone</surname><given-names>G</given-names></name><name><surname>Turck</surname><given-names>CW</given-names></name><name><surname>Dias-Neto</surname><given-names>E</given-names></name></person-group><article-title>Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis</article-title><source>J Neural Transm</source><year>2009</year><volume>116</volume><fpage>275</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">19034380</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name></person-group><article-title>Neuron-specific Enolase and myelin basic protein in cerebrospinal fluid of patients with first episode schizophrenia</article-title><source>J Huazhong Univ Sci Technolog Med Sci</source><year>2006</year><volume>26</volume><fpage>228</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">16850754</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Willson</surname><given-names>VJ</given-names></name><name><surname>Graham</surname><given-names>JG</given-names></name><name><surname>McQueen</surname><given-names>IN</given-names></name><name><surname>Thompson</surname><given-names>RJ</given-names></name></person-group><article-title>Immunoreactive aldolase C in cerebrospinal fluid of patients with neurological disorders</article-title><source>Ann Clin Biochem</source><year>1980</year><volume>17</volume><fpage>110</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">7406435</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnston-Wilson</surname><given-names>NL</given-names></name><name><surname>Sims</surname><given-names>CD</given-names></name><name><surname>Hofmann</surname><given-names>JP</given-names></name><name><surname>Anderson</surname><given-names>L</given-names></name><name><surname>Shore</surname><given-names>AD</given-names></name><name><surname>Torrey</surname><given-names>EF</given-names></name><name><surname>Yolken</surname><given-names>RH</given-names></name></person-group><article-title>Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium</article-title><source>Mol Psychiatry</source><year>2000</year><volume>5</volume><fpage>142</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10822341</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mehler-Wex</surname><given-names>C</given-names></name><name><surname>Duvigneau</surname><given-names>JC</given-names></name><name><surname>Hartl</surname><given-names>RT</given-names></name><name><surname>Ben-Shachar</surname><given-names>D</given-names></name><name><surname>Warnke</surname><given-names>A</given-names></name><name><surname>Gerlach</surname><given-names>M</given-names></name></person-group><article-title>Increased mRNA levels of the mitochondrial complex I 75-kDa subunit. A potential peripheral marker of early onset schizophrenia?</article-title><source>Eur Child Adolesc Psychiatry</source><year>2006</year><volume>15</volume><fpage>504</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16788776</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Altar</surname><given-names>CA</given-names></name><name><surname>Jurata</surname><given-names>LW</given-names></name><name><surname>Charles</surname><given-names>V</given-names></name><name><surname>Lemire</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Bukhman</surname><given-names>Y</given-names></name><name><surname>Young</surname><given-names>TA</given-names></name><name><surname>Bullard</surname><given-names>J</given-names></name><name><surname>Yokoe</surname><given-names>H</given-names></name><name><surname>Webster</surname><given-names>MJ</given-names></name><name><surname>Knable</surname><given-names>MB</given-names></name><name><surname>Brockman</surname><given-names>JA</given-names></name></person-group><article-title>Deficient hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial genes in multiple schizophrenia cohorts</article-title><source>Biol Psychiatry</source><year>2005</year><volume>58</volume><fpage>85</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">16038679</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ben-Shachar</surname><given-names>D</given-names></name></person-group><article-title>Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine</article-title><source>J Neurochem</source><year>2002</year><volume>83</volume><fpage>1241</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">12472879</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ben-Shachar</surname><given-names>D</given-names></name><name><surname>Laifenfeld</surname><given-names>D</given-names></name></person-group><article-title>Mitochondria, synaptic plasticity, and schizophrenia</article-title><source>Int Rev Neurobiol</source><year>2004</year><volume>59</volume><fpage>273</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">15006492</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khaitovich</surname><given-names>P</given-names></name><name><surname>Lockstone</surname><given-names>HE</given-names></name><name><surname>Wayland</surname><given-names>MT</given-names></name><name><surname>Tsang</surname><given-names>TM</given-names></name><name><surname>Jayatilaka</surname><given-names>SD</given-names></name><name><surname>Guo</surname><given-names>AJ</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Somel</surname><given-names>M</given-names></name><name><surname>Harris</surname><given-names>LW</given-names></name><name><surname>Holmes</surname><given-names>E</given-names></name><name><surname>Paabo</surname><given-names>S</given-names></name><name><surname>Bahn</surname><given-names>S</given-names></name></person-group><article-title>Metabolic changes in schizophrenia and human brain evolution</article-title><source>Genome Biol</source><year>2008</year><volume>9</volume><fpage>R124</fpage><pub-id pub-id-type="pmid">18681948</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Szymanski</surname><given-names>HV</given-names></name><name><surname>Orfanos</surname><given-names>A</given-names></name><name><surname>Narisawa</surname><given-names>K</given-names></name><name><surname>Grosz</surname><given-names>R</given-names></name><name><surname>Naylor</surname><given-names>EW</given-names></name></person-group><article-title>Dihydropteridine reductase in schizophrenic patients</article-title><source>Psychiatry Res</source><year>1985</year><volume>15</volume><fpage>115</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">3862143</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>JW</given-names></name><name><surname>Dodia</surname><given-names>C</given-names></name><name><surname>Feinstein</surname><given-names>SI</given-names></name><name><surname>Jain</surname><given-names>MK</given-names></name><name><surname>Fisher</surname><given-names>AB</given-names></name></person-group><article-title>1-Cys peroxiredoxin, a bifunctional enzyme with glutathione peroxidase and phospholipase A2 activities</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>28421</fpage><lpage>28427</lpage><pub-id pub-id-type="pmid">10893423</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahadik</surname><given-names>SP</given-names></name><name><surname>Pillai</surname><given-names>A</given-names></name><name><surname>Joshi</surname><given-names>S</given-names></name><name><surname>Foster</surname><given-names>A</given-names></name></person-group><article-title>Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia</article-title><source>Int Rev Psychiatry</source><year>2006</year><volume>18</volume><fpage>119</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">16777666</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gattaz</surname><given-names>WF</given-names></name><name><surname>H&#x000fc;bner</surname><given-names>CV</given-names></name><name><surname>Nevalainen</surname><given-names>TJ</given-names></name><name><surname>Thuren</surname><given-names>T</given-names></name><name><surname>Kinnunen</surname><given-names>PK</given-names></name></person-group><article-title>Increased serum phospholipase A2 activity in schizophrenia: a replication study</article-title><source>Biol Psychiatry</source><year>1990</year><volume>28</volume><fpage>495</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">2223919</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gattaz</surname><given-names>WF</given-names></name><name><surname>Brunner</surname><given-names>J</given-names></name></person-group><article-title>Phospholipase A2 and the hypofrontality hypothesis of schizophrenia</article-title><source>Prostaglandins Leukot Essent Fatty Acids</source><year>1996</year><volume>55</volume><fpage>109</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">8888132</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hwu</surname><given-names>HG</given-names></name><name><surname>Liu</surname><given-names>CM</given-names></name><name><surname>Fann</surname><given-names>CS</given-names></name><name><surname>Ou-Yang</surname><given-names>WC</given-names></name><name><surname>Lee</surname><given-names>SF</given-names></name></person-group><article-title>Linkage of schizophrenia with chromosome 1q loci in Taiwanese families</article-title><source>Mol Psychiatry</source><year>2003</year><volume>8</volume><fpage>445</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">12740602</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ben-Shachar</surname><given-names>D</given-names></name><name><surname>Bonne</surname><given-names>O</given-names></name><name><surname>Chisin</surname><given-names>R</given-names></name><name><surname>Klein</surname><given-names>E</given-names></name><name><surname>Lester</surname><given-names>H</given-names></name><name><surname>Aharon-Peretz</surname><given-names>J</given-names></name><name><surname>Yona</surname><given-names>I</given-names></name><name><surname>Freedman</surname><given-names>N</given-names></name></person-group><article-title>Cerebral glucose utilization and platelet mitochondrial complex I activity in schizophrenia: A FDG-PET study</article-title><source>Prog Neuropsychopharmacol Biol Psychiatry</source><year>2007</year><volume>31</volume><fpage>807</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">17329000</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>WS</given-names></name><name><surname>Faraone</surname><given-names>SV</given-names></name><name><surname>Su</surname><given-names>J</given-names></name><name><surname>Tarbox</surname><given-names>SI</given-names></name><name><surname>Van Eerdewegh</surname><given-names>P</given-names></name><name><surname>Tsuang</surname><given-names>MT</given-names></name></person-group><article-title>Evidence for linkage between regulatory enzymes in glycolysis and schizophrenia in a multiplex sample</article-title><source>Am J Med Genet B Neuropsychiatr Genet</source><year>2004</year><volume>127</volume><fpage>5</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">15108172</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Virgo</surname><given-names>L</given-names></name><name><surname>Humphries</surname><given-names>C</given-names></name><name><surname>Mortimer</surname><given-names>A</given-names></name><name><surname>Barnes</surname><given-names>T</given-names></name><name><surname>Hirsch</surname><given-names>S</given-names></name><name><surname>de Belleroche</surname><given-names>J</given-names></name></person-group><article-title>Cholecystokinin messenger RNA deficit in frontal and temporal cerebral cortex in schizophrenia</article-title><source>Biol Psychiatry</source><year>1995</year><volume>37</volume><fpage>694</fpage><lpage>701</lpage><pub-id pub-id-type="pmid">7640324</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Denarier</surname><given-names>E</given-names></name><name><surname>Aguezzoul</surname><given-names>M</given-names></name><name><surname>Jolly</surname><given-names>C</given-names></name><name><surname>Vourc'h</surname><given-names>C</given-names></name><name><surname>Roure</surname><given-names>A</given-names></name><name><surname>Andrieux</surname><given-names>A</given-names></name><name><surname>Bosc</surname><given-names>C</given-names></name><name><surname>Job</surname><given-names>D</given-names></name></person-group><article-title>Genomic structure and chromosomal mapping of the mouse STOP gene (Mtap6)</article-title><source>Biochem Biophys Res Commun</source><year>1998</year><volume>243</volume><fpage>791</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9501006</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andrieux</surname><given-names>A</given-names></name><name><surname>Salin</surname><given-names>PA</given-names></name><name><surname>Vernet</surname><given-names>M</given-names></name><name><surname>Kujala</surname><given-names>P</given-names></name><name><surname>Baratier</surname><given-names>J</given-names></name><name><surname>Gory-Faur&#x000e9;</surname><given-names>S</given-names></name><name><surname>Bosc</surname><given-names>C</given-names></name><name><surname>Pointu</surname><given-names>H</given-names></name><name><surname>Proietto</surname><given-names>D</given-names></name><name><surname>Schweitzer</surname><given-names>A</given-names></name><name><surname>Denarier</surname><given-names>E</given-names></name><name><surname>Klumperman</surname><given-names>J</given-names></name><name><surname>Job</surname><given-names>D</given-names></name></person-group><article-title>The suppression of brain cold-stable microtubules in mice induces synaptic defects associated with neuroleptic-sensitive behavioral disorders</article-title><source>Genes Dev</source><year>2002</year><volume>16</volume><fpage>2350</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">12231625</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brun</surname><given-names>P</given-names></name><name><surname>B&#x000e9;gou</surname><given-names>M</given-names></name><name><surname>Andrieux</surname><given-names>A</given-names></name><name><surname>Mouly-Badina</surname><given-names>L</given-names></name><name><surname>Clerget</surname><given-names>M</given-names></name><name><surname>Schweitzer</surname><given-names>A</given-names></name><name><surname>Scarna</surname><given-names>H</given-names></name><name><surname>Renaud</surname><given-names>B</given-names></name><name><surname>Job</surname><given-names>D</given-names></name><name><surname>Suaud-Chagny</surname><given-names>MF</given-names></name></person-group><article-title>Dopaminergic transmission in STOP null mice</article-title><source>J Neurochem</source><year>2005</year><volume>94</volume><fpage>63</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">15953350</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steffek</surname><given-names>AE</given-names></name><name><surname>McCullumsmith</surname><given-names>RE</given-names></name><name><surname>Haroutunian</surname><given-names>V</given-names></name><name><surname>Meador-Woodruff</surname><given-names>JH</given-names></name></person-group><article-title>Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia</article-title><source>Schizophr Res</source><year>2008</year><volume>103</volume><fpage>71</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">18562176</pub-id></citation></ref><ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Thompson</surname><given-names>SN</given-names></name><name><surname>Hall</surname><given-names>ED</given-names></name><name><surname>Guttmann</surname><given-names>RP</given-names></name></person-group><article-title>Identification and characterization of PEBP as a calpain substrate</article-title><source>J Neurochem</source><year>2006</year><volume>99</volume><fpage>1133</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">17018026</pub-id></citation></ref><ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Theroux</surname><given-names>S</given-names></name><name><surname>Pereira</surname><given-names>M</given-names></name><name><surname>Casten</surname><given-names>KS</given-names></name><name><surname>Burwell</surname><given-names>RD</given-names></name><name><surname>Yeung</surname><given-names>KC</given-names></name><name><surname>Sedivy</surname><given-names>JM</given-names></name><name><surname>Klysik</surname><given-names>J</given-names></name></person-group><article-title>Raf kinase inhibitory protein knockout mice: expression in the brain and olfaction deficit</article-title><source>Brain Res Bull</source><year>2007</year><volume>71</volume><fpage>559</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">17292798</pub-id></citation></ref><ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>AJ</given-names></name><name><surname>Holsinger</surname><given-names>RM</given-names></name><name><surname>McLean</surname><given-names>CA</given-names></name><name><surname>Tan</surname><given-names>SS</given-names></name><name><surname>Scott</surname><given-names>HS</given-names></name><name><surname>Cardamone</surname><given-names>T</given-names></name><name><surname>Cappai</surname><given-names>R</given-names></name><name><surname>Masters</surname><given-names>CL</given-names></name><name><surname>Li</surname><given-names>QX</given-names></name></person-group><article-title>Decreased phosphatidylethanolamine binding protein expression correlates with Abeta accumulation in the Tg2576 mouse model of Alzheimer's disease</article-title><source>Neurobiol Aging</source><year>2006</year><volume>27</volume><fpage>614</fpage><lpage>623</lpage><pub-id pub-id-type="pmid">15941609</pub-id></citation></ref><ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meehan</surname><given-names>WJ</given-names></name><name><surname>Welch</surname><given-names>DR</given-names></name></person-group><article-title>Breast cancer metastasis suppressor 1: update</article-title><source>Clin Exp Metastasis</source><year>2003</year><volume>20</volume><fpage>45</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">12650606</pub-id></citation></ref></ref-list></back></article> 